Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

BACKGROUND: Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (PD-L1), highlighting the need for a more sensitive biomarker. We hypothesize th...

Descripción completa

Detalles Bibliográficos
Autores principales: Smithy, James W., Moore, Lauren M., Pelekanou, Vasiliki, Rehman, Jamaal, Gaule, Patricia, Wong, Pok Fai, Neumeister, Veronique M., Sznol, Mario, Kluger, Harriet M., Rimm, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359951/
https://www.ncbi.nlm.nih.gov/pubmed/28331615
http://dx.doi.org/10.1186/s40425-017-0229-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359951/
https://www.ncbi.nlm.nih.gov/pubmed/28331615
http://dx.doi.org/10.1186/s40425-017-0229-2

Ejemplares similares